白细胞免疫球蛋白样受体B3 (LILRB3)的免疫学功能及人类恶性肿瘤相关性研究
Investigations into the Immunological Functions of LILRB3 and Its Association with Human Malignancies
DOI: 10.12677/acm.2024.1461852, PDF,   
作者: 丛子翔, 牛志宏*：山东大学齐鲁医学院，山东 济南；山东省立医院泌尿外科，山东 济南
关键词: LILRB3；恶性肿瘤；免疫抑制；靶向治疗；LILRB3； Malignant Tumors； Immunosuppression； Targeted Therapy
摘要: 目前，恶性肿瘤仍是全球范围内人类疾病死亡的主要原因之一。越来越多的研究揭示，恶性肿瘤的发生进展与基因表达密切相关。因此，通过转录组学研究寻找恶性肿瘤相关的生物标志物已成为癌症研究的热门领域。白细胞免疫球蛋白样受体B家族成员3 (Leukocyte immunoglobulin-like receptor subfamily B member 3, LILRB3)是LILR家族的一员，在免疫细胞中广泛表达，主要抑制免疫反应并介导耐受。LILRB3的异常表达与一系列病理学过程相关，包括感染和肿瘤进展过程中的免疫功能抑制，这表明LILRB3可能是免疫疗法的潜在候选靶点。本综述将概述这一广泛的免疫受体的免疫学功能和肿瘤相关性，总结了其在急性髓系白血病白血病、结直肠癌、神经胶质瘤等肿瘤中的研究进展，希望能够为靶向LILR治疗从癌症到自身免疫等多种疾病研究提供新的思路。
Abstract: Currently, malignant tumors remain one of the principal causes of mortality from human diseases globally. An increasing body of research has unveiled that the genesis and progression of malignant tumors are intimately associated with gene expression. Consequently, the quest for biomarkers related to malignant tumors through transcriptomic studies has emerged as a fervent area of cancer research. The Leukocyte immunoglobulin-like receptor subfamily B member 3 (LILRB3), a constituent of the LILR family, is ubiquitously expressed in immune cells, primarily inhibiting immune responses and mediating tolerance. The aberrant expression of LILRB3 is linked with a spectrum of pathological processes, including the suppression of immune function during infections and tumor progression, suggesting LILRB3 as a potential target for immunotherapy. This review aims to encapsulate the immunological functions and tumor relevance of this expansive immune receptor, summarizing its research progress in malignancies such as acute myeloid leukemia, colorectal cancer, and glioma, in hopes of furnishing novel insights for targeted LILR therapy in a wide array of diseases ranging from cancer to autoimmunity.
文章引用：丛子翔, 牛志宏. 白细胞免疫球蛋白样受体B3 (LILRB3)的免疫学功能及人类恶性肿瘤相关性研究[J]. 临床医学进展, 2024, 14(6): 858-866. https://doi.org/10.12677/acm.2024.1461852

参考文献

[1] Motzer, R.J., Rane, P.P., Saretsky, T.L., Pawar, D., Martin Nguyen, A., Sundaram, M., et al. (2023) Patient-Reported Outcome Measurement and Reporting for Patients with Advanced Renal Cell Carcinoma: A Systematic Literature Review. European Urology, 84, 406-417. [Google Scholar] [CrossRef] [PubMed]
[2] Sánchez-Gastaldo, A., Kempf, E., González del Alba, A., et al. (2017) Systemic Treatment of Renal Cell Cancer: A Comprehensive Review. Cancer Treatment Reviews, 60, 77-89. [Google Scholar] [CrossRef] [PubMed]
[3] Tay, C., Tanaka, A. and Sakaguchi, S. (2023) Tumor-Infiltrating Regulatory T Cells as Targets of Cancer Immunotherapy. Cancer Cell, 41, 450-465. [Google Scholar] [CrossRef] [PubMed]
[4] Cosman, D., Fanger, N., Borges, L., Kubin, M., Chin, W., Peterson, L., et al. (1997) A Novel Immunoglobulin Superfamily Receptor for Cellular and Viral MHC Class I Molecules. Immunity, 7, 273-282. [Google Scholar] [CrossRef] [PubMed]
[5] Colonna, M., Samaridis, J., Cella, M., Angman, L., Allen, R.L., O’Callaghan, C.A., et al. (1998) Cutting Edge: Human Myelomonocytic Cells Express an Inhibitory Receptor for Classical and Nonclassical MHC Class I Molecules. The Journal of Immunology, 160, 3096-3100. [Google Scholar] [CrossRef] 
[6] Hirayasu, K. and Arase, H. (2018) Leukocyte Immunoglobulin-Like Receptor (LILR). In: Choi, S., Ed., Encyclopedia of Signaling Molecules, Springer International Publishing, 2854-2861. [Google Scholar] [CrossRef] 
[7] Zhuang, Q., Liu, Y., Wang, H., et al. (2023) LILRB3 Suppresses Immunity in Glioma and Is Associated with Poor Prognosis. Clinical and Translational Medicine, 13, e1396. [Google Scholar] [CrossRef] [PubMed]
[8] Shi, W., Zhang, F., Chen, X., Wang, S., Zhang, H., Yang, Z., et al. (2022) Tumor-Derived Immunoglobulin Like Transcript 5 Induces Suppressive Immunocyte Infiltration in Colorectal Cancer. Cancer Science, 113, 1939-1954. [Google Scholar] [CrossRef] [PubMed]
[9] Wu, G., Xu, Y., Schultz, R.D., Chen, H., Xie, J., Deng, M., et al. (2021) LILRB3 Supports Acute Myeloid Leukemia Development and Regulates T-Cell Antitumor Immune Responses through the TRAF2-cFLIP-Nf-κB Signaling Axis. Nature Cancer, 2, 1170-1184. [Google Scholar] [CrossRef] [PubMed]
[10] Storm, L., Bruijnesteijn, J., De Groot, N.G., et al. (2021) The Genomic Organization of the LILR Region Remained Largely Conserved Throughout Primate Evolution: Implications for Health and Disease. Frontiers in Immunology, 12, Article 716289. [Google Scholar] [CrossRef] [PubMed]
[11] Sambrook, J.G., Bashirova, A., Andersen, H., et al. (2006) Identification of the Ancestral Killer Immunoglobulin-Like Receptor Gene in Primates. BMC Genomics, 7, Article No. 209. [Google Scholar] [CrossRef] [PubMed]
[12] Bashirova, A.A., Apps, R., Vince, N., Mochalova, Y., Yu, X.G. and Carrington, M. (2013) Diversity of the Human LILRB3/A6 Locus Encoding a Myeloid Inhibitory and Activating Receptor Pair. Immunogenetics, 66, 1-8. [Google Scholar] [CrossRef] [PubMed]
[13] Pfistershammer, K., Lawitschka, A., Klauser, C., Leitner, J., Weigl, R., Heemskerk, M.H.M., et al. (2009) Allogeneic Disparities in Immunoglobulin-Like Transcript 5 Induce Potent Antibody Responses in Hematopoietic Stem Cell Transplant Recipients. Blood, 114, 2323-2332. [Google Scholar] [CrossRef] [PubMed]
[14] Hirayasu, K., Sun, J., Hasegawa, G., et al. (2021) Characterization of LILRB3 and LILRA6 Allelic Variants in the Japanese Population. Journal of Human Genetics, 66, 739-748. [Google Scholar] [CrossRef] [PubMed]
[15] Bashirova, A.A., Kasprzak, W., O’hUigin, C. and Carrington, M. (2022) Distinct Frequency Patterns of LILRB3 and LILRA6 Allelic Variants in Europeans. Immunogenetics, 75, 263-267. [Google Scholar] [CrossRef] [PubMed]
[16] Anderson, K.J. and Allen, R.L. (2009) Regulation of T-Cell Immunity by Leucocyte Immunoglobulin-Like Receptors: Innate Immune Receptors for Self on Antigen-Presenting Cells. Immunology, 127, 8-17. [Google Scholar] [CrossRef] [PubMed]
[17] Zhou, J., Wang, Y., Huang, G., Yang, M., Zhu, Y., Jin, C., et al. (2023) LilrB3 Is a Putative Cell Surface Receptor of APOE4. Cell Research, 33, 116-130. [Google Scholar] [CrossRef] [PubMed]
[18] Redondo-García, S., Barritt, C., Papagregoriou, C., et al. (2023) Human Leukocyte Immunoglobulin-Like Receptors in Health and Disease. Frontiers in Immunology, 14, Article 1282874. [Google Scholar] [CrossRef] [PubMed]
[19] Jones, D.C., Hewitt, C.R.A., López-Álvarez, M.R., Jahnke, M., Russell, A.I., Radjabova, V., et al. (2016) Allele-Specific Recognition by LILRB3 and LILRA6 of a Cytokeratin 8-Associated Ligand on Necrotic Glandular Epithelial Cells. Oncotarget, 7, 15618-15631. [Google Scholar] [CrossRef] [PubMed]
[20] van der Touw, W., Kang, K., Luan, Y., Ma, G., Mai, S., Qin, L., et al. (2018) Glatiramer Acetate Enhances Myeloid-Derived Suppressor Cell Function via Recognition of Paired Ig-Like Receptor B. The Journal of Immunology, 201, 1727-1734. [Google Scholar] [CrossRef] [PubMed]
[21] Lasry, A. and Aifantis, I. (2021) LILRB3 as a Regulator of AML Survival. Nature Cancer, 2, 1122-1123. [Google Scholar] [CrossRef] [PubMed]
[22] Hirayasu, K. and Arase, H. (2015) Functional and Genetic Diversity of Leukocyte Immunoglobulin-Like Receptor and Implication for Disease Associations. Journal of Human Genetics, 60, 703-708. [Google Scholar] [CrossRef] [PubMed]
[23] An, H., Chandra, V., Piraino, B., Borges, L., Geczy, C., Mcneil, H.P., et al. (2010) Soluble LILRA3, a Potential Natural Antiinflammatory Protein, Is Increased in Patients with Rheumatoid Arthritis and Is Tightly Regulated by Interleukin 10, Tumor Necrosis Factor-α, and Interferon-γ. The Journal of Rheumatology, 37, 1596-1606. [Google Scholar] [CrossRef] [PubMed]
[24] Lebbink, R.J., van den Berg, M.C.W., de Ruiter, T., Raynal, N., van Roon, J.A.G., Lenting, P.J., et al. (2008) The Soluble Leukocyte-Associated Ig-Like Receptor (LAIR)-2 Antagonizes the Collagen/LAIR-1 Inhibitory Immune Interaction. The Journal of Immunology, 180, 1662-1669. [Google Scholar] [CrossRef] [PubMed]
[25] Deng, M., Chen, H., Liu, X., Huang, R., He, Y., Yoo, B., et al. (2021) Leukocyte Immunoglobulin-Like Receptor Subfamily B: Therapeutic Targets in Cancer. Antibody Therapeutics, 4, 16-33. [Google Scholar] [CrossRef] [PubMed]
[26] Takeda, K. and Nakamura, A. (2017) Regulation of Immune and Neural Function via Leukocyte Ig-Like Receptors. The Journal of Biochemistry, 162, 73-80. [Google Scholar] [CrossRef] [PubMed]
[27] Kim, T., Vidal, G.S., Djurisic, M., William, C.M., Birnbaum, M.E., Garcia, K.C., et al. (2013) Human LilrB2 Is a β-Amyloid Receptor and Its Murine Homolog PirB Regulates Synaptic Plasticity in an Alzheimer’s Model. Science, 341, 1399-1404. [Google Scholar] [CrossRef] [PubMed]
[28] Karo-Atar, D., Moshkovits, I., Eickelberg, O., Königshoff, M. and Munitz, A. (2013) Paired Immunoglobulin-Like Receptor-B Inhibits Pulmonary Fibrosis by Suppressing Profibrogenic Properties of Alveolar Macrophages. American Journal of Respiratory Cell and Molecular Biology, 48, 456-464. [Google Scholar] [CrossRef] [PubMed]
[29] Cheng, H., Mohammed, F., Nam, G., Chen, Y., Qi, J., Garner, L.I., et al. (2011) Crystal Structure of Leukocyte Ig-Like Receptor LILRB4 (ILT3/LIR-5/CD85k). Journal of Biological Chemistry, 286, 18013-18025. [Google Scholar] [CrossRef] [PubMed]
[30] Ayukawa, S., Kamoshita, N., Nakayama, J., Teramoto, R., Pishesha, N., Ohba, K., et al. (2021) Epithelial Cells Remove Precancerous Cells by Cell Competition via MHC Class I-LILRB3 Interaction. Nature Immunology, 22, 1391-1402. [Google Scholar] [CrossRef] [PubMed]
[31] Wong, C.C. and Yu, J. (2022) MHC Class I-LILRB3 Delivers a Punch to Eliminate Precancerous Cells. Cellular & Molecular Immunology, 19, 655-656. [Google Scholar] [CrossRef] [PubMed]
[32] Zheng, J., Umikawa, M., Cui, C., Li, J., Chen, X., Zhang, C., et al. (2012) Inhibitory Receptors Bind ANGPTLs and Support Blood Stem Cells and Leukaemia Development. Nature, 485, 656-660. [Google Scholar] [CrossRef] [PubMed]
[33] Cabia, B., Andrade, S., Carreira, M.C., Casanueva, F.F. and Crujeiras, A.B. (2016) A Role for Novel Adipose Tissue-Secreted Factors in Obesity-Related Carcinogenesis. Obesity Reviews, 17, 361-376. [Google Scholar] [CrossRef] [PubMed]
[34] Thorin-Trescases, N., Labbé, P., Mury, P., Lambert, M. and Thorin, E. (2021) Angptl2 Is a Marker of Cellular Senescence: The Physiological and Pathophysiological Impact of Angptl2-Related Senescence. International Journal of Molecular Sciences, 22, Article 12232. [Google Scholar] [CrossRef] [PubMed]
[35] Blumenfeld, J., Yip, O., Kim, M.J. and Huang, Y. (2024) Cell Type-Specific Roles of APOE4 in Alzheimer Disease. Nature Reviews Neuroscience, 25, 91-110. [Google Scholar] [CrossRef] [PubMed]
[36] Huang, R., Liu, X., Kim, J., Deng, H., Deng, M., Gui, X., et al. (2023) LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development. Cancer Immunology Research, 12, 350-362. [Google Scholar] [CrossRef] [PubMed]
[37] Hofer, J., Forster, F., Isenman, D.E., Wahrmann, M., Leitner, J., Hölzl, M.A., et al. (2015) Ig-Like Transcript 4 as a Cellular Receptor for Soluble Complement Fragment C4d. The FASEB Journal, 30, 1492-1503. [Google Scholar] [CrossRef] [PubMed]
[38] Nakayama, M., Underhill, D.M., Petersen, T.W., Li, B., Kitamura, T., Takai, T., et al. (2007) Paired Ig-Like Receptors Bind to Bacteria and Shape TLR-Mediated Cytokine Production. The Journal of Immunology, 178, 4250-4259. [Google Scholar] [CrossRef] [PubMed]
[39] van Rees, D.J., Szilagyi, K., Kuijpers, T.W., Matlung, H.L. and van den Berg, T.K. (2016) Immunoreceptors on Neutrophils. Seminars in Immunology, 28, 94-108. [Google Scholar] [CrossRef] [PubMed]
[40] Kuroki, K., Furukawa, A. and Maenaka, K. (2012) Molecular Recognition of Paired Receptors in the Immune System. Frontiers in Microbiology, 3, Article 429. [Google Scholar] [CrossRef] [PubMed]
[41] Favier, B. (2016) Regulation of Neutrophil Functions through Inhibitory Receptors: An Emerging Paradigm in Health and Disease. Immunological Reviews, 273, 140-155. [Google Scholar] [CrossRef] [PubMed]
[42] Lewis Marffy, A.L. and McCarthy, A.J. (2020) Leukocyte Immunoglobulin-Like Receptors (LILRs) on Human Neutrophils: Modulators of Infection and Immunity. Frontiers in Immunology, 11, Article 857.
[43] Zhao, Y., van Woudenbergh, E., Zhu, J., Heck, A.J.R., van Kessel, K.P.M., de Haas, C.J.C., et al. (2020) The Orphan Immune Receptor LILRB3 Modulates Fc Receptor-Mediated Functions of Neutrophils. The Journal of Immunology, 204, 954-966. [Google Scholar] [CrossRef] [PubMed]
[44] Sloane, D.E., Tedla, N., Awoniyi, M., MacGlashan, D.W., Borges, L., Austen, K.F., et al. (2004) Leukocyte Immunoglobulin-Like Receptors: Novel Innate Receptors for Human Basophil Activation and Inhibition. Blood, 104, 2832-2839. [Google Scholar] [CrossRef] [PubMed]
[45] Uehara, T., Bléry, M., Kang, D., Chen, C., Ho, L.H., Gartland, G.L., et al. (2001) Inhibition of Ige-Mediated Mast Cell Activation by the Paired Ig-Like Receptor PIR-b. Journal of Clinical Investigation, 108, 1041-1050. [Google Scholar] [CrossRef] [PubMed]
[46] Yeboah, M., Papagregoriou, C., Jones, D.C., et al. (2020) LILRB3 (ILT5) Is a Myeloid Cell Checkpoint that Elicits Profound Immunomodulation. JCI Insight, 5, e141593. [Google Scholar] [CrossRef] [PubMed]
[47] He, L., Jhong, J.-H., Chen, Q., Huang, K.-Y., Strittmatter, K., Kreuzer, J., et al. (2021) Global Characterization of Macrophage Polarization Mechanisms and Identification of M2-Type Polarization Inhibitors. Cell Reports, 37, Article 109955. [Google Scholar] [CrossRef] [PubMed]
[48] 戈文珂, 吴卫兵. 肿瘤微环境中肿瘤相关巨噬细胞极化的影响因素及其意义[J]. 中国肺癌杂志, 2023, 26(3): 228-237.
[49] Ogawa, K., Funaba, M., Chen, Y. and Tsujimoto, M. (2006) Activin a Functions as a Th2 Cytokine in the Promotion of the Alternative Activation of Macrophages. The Journal of Immunology, 177, 6787-6794. [Google Scholar] [CrossRef] [PubMed]
[50] Picarda, E., Ohaegbulam, K.C. and Zang, X. (2016) Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy. Clinical Cancer Research, 22, 3425-3431. [Google Scholar] [CrossRef] [PubMed]
[51] Vlaicu, P., Mertins, P., Mayr, T., et al. (2013) Monocytes/Macrophages Support Mammary Tumor Invasivity by Co-Secreting Lineage-Specific EGFR Ligands and a STAT3 Activator. BMC Cancer, 13, Article No. 197. [Google Scholar] [CrossRef] [PubMed]
[52] Ma, G., Pan, P.-Y., Eisenstein, S., Divino, C.M., Lowell, C.A., Takai, T., et al. (2011) Paired Immunoglobin-Like Receptor-B Regulates the Suppressive Function and Fate of Myeloid-Derived Suppressor Cells. Immunity, 34, 385-395. [Google Scholar] [CrossRef] [PubMed]
[53] Liu, H. (2021) Emerging Agents and Regimens for AML. Journal of Hematology & Oncology, 14, Article No. 49. [Google Scholar] [CrossRef] [PubMed]
[54] Mai, S., Hodges, A., Chen, H., Zhang, J., Wang, Y., Liu, Y., et al. (2023) LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-Cell Therapy. Cancer Research, 83, 4047-4062. [Google Scholar] [CrossRef] [PubMed]
[55] Chen, Y., Gao, D.-Y. and Huang, L. (2015) In vivo Delivery of miRNAs for Cancer Therapy: Challenges and Strategies. Advanced Drug Delivery Reviews, 81, 128-141. [Google Scholar] [CrossRef] [PubMed]
[56] Cen, Q., Chen, J., Guo, J., et al. (2024) CLPs-miR-103a-2-5p Inhibits Proliferation and Promotes Cell Apoptosis in AML Cells by Targeting LILRB3 and Nrf2/HO-1 Axis, Regulating CD8+ T Cell Response. Journal of Translational Medicine, 22, Article 278. [Google Scholar] [CrossRef] [PubMed]
[57] Dekker, E., Tanis, P.J., Vleugels, J.L.A., Kasi, P.M. and Wallace, M.B. (2019) Colorectal Cancer. The Lancet, 394, 1467-1480. [Google Scholar] [CrossRef] [PubMed]
[58] Xu, S., Tang, L., Li, X., et al. (2020) Immunotherapy for Glioma: Current Management and Future Application. Cancer Letters, 476, 1-12. [Google Scholar] [CrossRef] [PubMed]
[59] Hara, T., Chanoch-Myers, R., Mathewson, N.D., et al. (2021) Interactions between Cancer Cells and Immune Cells Drive Transitions to Mesenchymal-Like States in Glioblastoma. Cancer Cell, 39, 779-792. [Google Scholar] [CrossRef] [PubMed]

为你推荐